Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.46 |
| ▸ | RAB9A | P51151 | 9/20 | 0.46 |
| ▸ | PKM | P14618 | 4/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22839376 | 0.83 | NPC1 (0.52) | NPC1RAB9APKMGAASMN1; SMN2 | |
| SCHEMBL16657872 | 0.76 | RAB9A (0.50) | NPC1RAB9APKMGAASMN1; SMN2 | |
| SCHEMBL19057796 | 0.75 | TGM2 (0.44) | NPC1RAB9AGAASMN1; SMN2KDM4E | |
| SCHEMBL18639384 | 0.75 | SMN1; SMN2 (0.50) | NPC1RAB9APKMGAASMN1; SMN2 | |
| SCHEMBL22268029 | 0.71 | GAA (0.42) | NPC1RAB9APKMGAAKDM4E | |
| SCHEMBL20143328 | 0.71 | NPC1 (0.45) | NPC1RAB9APKMGAASMN1; SMN2 | |
| SCHEMBL19269582 | 0.71 | NPC1 (0.45) | NPC1RAB9APKMGAASMN1; SMN2 | |
| SCHEMBL21594549 | 0.70 | MAPT (0.46) | RAB9AGAASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL21583063 | 0.70 | NPC1 (0.44) | NPC1RAB9APKMGAASMN1; SMN2 | |
| SCHEMBL19709471 | 0.70 | SCN9A (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346765-A1 | METHODS OF TREATING XANTHINE OXIDASE-RELATED DISEASES WITH NIFLUMIC ACID AND DERIVATIVES THEREOF | BAYLOR COLLEGE OF MEDICINE (US) | 2023-11-02 | — | — | US | disclosed |
| US-20200239444-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2020-07-30 | — | — | US | disclosed |
| US-10717724-B2 | Compounds useful for treating cancer | ABIVAX (FR) | 2020-07-21 | — | — | US | disclosed |
| US-20180222888-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | ABIVAX (FR) | 2018-08-09 | — | — | US | disclosed |
| US-9969715-B2 | Compounds useful for treating cancer | ABIVAX (FR) | 2018-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180222888-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | PRMT7, PRMT6, RRM2 | NPC1 1881/4885RAB9A 2467/4885PKM 3074/4885 |
| US-20230346765-A1 | METHODS OF TREATING XANTHINE OXIDASE-RELATED DISEASES WITH NIFLUMIC ACID AND DERIVATIVES THEREOF | XDH, PNPO, PNP | NPC1 441/4885RAB9A 3210/4885PKM 1333/4885 |
| US-10717724-B2 | Compounds useful for treating cancer | PRMT7, PRMT6, RRM2 | NPC1 1881/4885RAB9A 2467/4885PKM 3074/4885 |
| US-20200239444-A1 | COMPOUNDS USEFUL FOR TREATING CANCER | PRMT7, PRMT6, RRM2 | NPC1 2247/4885RAB9A 2637/4885PKM 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.